Oklahoma Clinical Trials Report — July 2026

Oklahomans considering a clinical trial should check eligibility now: 39 recruiting studies are expected to close within the next 90 days. Three of those trials accept healthy volunteers, creating a limited window for people without a diagnosed condition. Statewide, 770 trials are recruiting across 22 cities and 384 research sites.

July brought 9 new trials, down from 20 in May and 15 in June. The monthly total has fluctuated during 2026, reaching 20 in June before falling to 9 in July. Even with fewer openings, the new studies include a large Phase 3 weight-management trial from Novo Nordisk, a Phase 3 schizophrenia relapse-prevention study from Karuna Therapeutics, and University of Oklahoma research spanning cancer detection, cannabis packaging, and endometrial cancer.

Closing-soon studies create the most immediate opportunity

Patients whose conditions match a closing study should begin screening as soon as possible. Enrollment deadlines can change, and eligibility reviews may require medical records, laboratory testing, or other steps before participation is confirmed.

• Atopic dermatitis — 3 closing-soon trials
• Endometrial cancer, breast cancer, stroke, prostate cancer, and alcohol use disorder — 2 each
• Agitation or psychomotor symptoms, aggression, acute myeloid leukemia, and AML — 1 each

The three closing-soon studies that accept healthy volunteers may be especially time-sensitive for people interested in research without a condition-specific treatment need. Oklahoma has 53 recruiting studies statewide that accept healthy volunteers overall, but only 1 of the 9 trials opened in July includes healthy volunteers. Healthy adults should search now rather than wait for a larger wave of new opportunities.

New studies range from cancer screening to weight management

The new-trial mix reflects both medical treatment and research into behavior, decision-making, and community health. Four new studies are drug trials, three are behavioral studies, one uses a device, and one evaluates a dietary supplement. New research addresses bladder, breast, colon, and endometrial cancers, as well as burnout, cannabis use, decision-making, first responders, and food insecurity.

One of the broadest new opportunities is University of Oklahoma study NCT07732686, “Analysis of Breath Volatile Organic Compounds Using Mass Spectrometry.” With planned enrollment of 2,000 participants, the study will evaluate whether chemical signatures in exhaled breath could help detect cancer earlier. It is listed without a phase and focuses on a potential screening approach rather than a cancer treatment.

Two major Phase 3 drug trials stand out for participants who meet their condition requirements:

• NCT07720271 — Novo Nordisk’s Phase 3 AMAZE 9 study of once-daily zenagamtide tablets for people with excess body weight. The study plans to enroll 950 participants and compares zenagamtide with placebo.
• NCT07686263 — Karuna Therapeutics, a Bristol Myers Squibb company, is sponsoring a Phase 3 relapse-prevention study of KarXT in schizophrenia. The trial plans to enroll 472 participants.
• NCT07737795 — The University of Oklahoma’s Phase 2 study evaluates adding weekly OK-1 paclitaxel for advanced or recurrent endometrial cancer. Planned enrollment is 66 participants.
• NCT07701304 — University of Oklahoma researchers are testing warning labels for retail cannabis products through a discrete choice experiment involving 450 participants.
• NCT07732686 — University of Oklahoma’s breath-analysis study examines whether volatile organic compounds may provide an early cancer-screening signal, with planned enrollment of 2,000.

The sponsor landscape is led by the University of Oklahoma, which opened 4 trials. Oklahoma State University opened one, while Novo Nordisk, Evopoint Biosciences, Karuna Therapeutics, and Laureate Institute for Brain Research each sponsored one. Six new studies were classified as “other” rather than industry-sponsored, and 3 were industry-sponsored. This gives prospective participants a mix of university-led observational and behavioral research alongside pharmaceutical development.

Oklahoma City dominates new openings, with smaller hubs also active

New trial activity is concentrated in Oklahoma City: 6 of the 9 July openings are located there. Norman, Stillwater, and Tulsa each added 1 new trial.

• Oklahoma City — 6 new trials
• Norman — 1
• Stillwater — 1
• Tulsa — 1

The pattern shows a strong metropolitan and university-centered concentration, particularly around Oklahoma City and the state’s major academic communities. However, the broader recruiting network includes 22 cities and 384 research sites, so residents outside the four cities with July openings may still find active studies. Searching by condition and acceptable travel distance can reveal opportunities not represented among this month’s new locations.

Older adults are included in most July eligibility profiles

None of the new trials include children, and no new study is listed as male-only. One is female-only. Older adults are included in 8 of the 9 new trials, making age-appropriate research a prominent feature of July’s openings. People should still review the exact age limits and health requirements, because “including older adults” does not mean every older applicant will qualify.

Healthy volunteers have fewer new options than patients with specific conditions. Only one July opening accepts healthy volunteers, compared with 53 recruiting healthy-volunteer studies statewide. The three closing-soon studies with healthy-volunteer eligibility deserve particular attention from adults who want to contribute to research but do not have cancer, schizophrenia, obesity, or another target condition.

Patients with atopic dermatitis, endometrial cancer, breast cancer, stroke, prostate cancer, or alcohol use disorder should also act promptly because these conditions account for the largest groups of studies approaching closure. As Oklahoma moves into the second half of 2026, additional openings may broaden access beyond Oklahoma City, while current studies continue to change their enrollment timelines and eligibility requirements.